DepoMed Dodges Patent Infringement Lawsuit

August 4, 2010 · Filed Under Epilepsy · Comment 

DepoMed Inc. (NASDAQ: DEPO) was up $0.47 (16.61%) today to $3.30 on news that no patent infringement lawsuit has been filed against the company over their experimental neuropathic pain drug, DM-1796.  As a result, the company expects to gain marketing approval of the drug in the first quarter of next year.

DepoMed Inc. is a biopharm company most well known for its drugs GLUMETZA, used for the treatment of type 2 diabetes, and Proquin XR, used for the treatment of uncomplicated urinary tract infection.  DM-1796 will be used for the treatment of epileptic seizures.

-Michael B. Sauter

Catalyst Continues Upward Trend With 15% Gain

July 26, 2010 · Filed Under Epilepsy · Comment 

Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX) a small biopharm company, gained $0.16 (14.81%) in trading today on no news. The Company had been trending upward for the last couple of weeks.

CPRX is a development-stage biopharmaceutical company, focuses on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy.

-Michael B. Sauter

Cyberonics Beats Wall Street Sales Forecasts, Up 12%

June 3, 2010 · Filed Under Depression, Devices, Epilepsy · Comment 

Cyberonics Inc. (NASDAQ: CBYX) a neuromodulation company specializing in surgically implanted devices used to treat neurological disorders  is up nearly 12% to $20.89 after exceeding analyst estimates on fourth quarter earnings. Their primary product, a device which is uses vague nerve stimulation to treat epilepsy and depression, sold far better than expected.

    Subscribe to BioHealth Investor BioHealth Investor RSS Feed